WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 300147

CAS#: 274693-27-5

Description: Ticagrelor, also known as AZD-6140 and AR-C 126532XX, is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved in 2011. Ticagrelor is an antagonist of the P2Y12 receptor. Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19.

Chemical Structure

CAS# 274693-27-5

Theoretical Analysis

MedKoo Cat#: 300147
Name: Ticagrelor
CAS#: 274693-27-5
Chemical Formula: C23H28F2N6O4S
Exact Mass: 522.18608
Molecular Weight: 522.57
Elemental Analysis: C, 52.86; H, 5.40; F, 7.27; N, 16.08; O, 12.25; S, 6.14

Price and Availability

Size Price Availability Quantity
1.0g USD 250.0 Same day
2.0g USD 450.0 Same day
5.0g USD 750.0 Same day
10.0g USD 950.0 Same day
20.0g USD 1450.0 Same day
50.0g USD 1950.0 Same day
100.0g USD 3650.0 Same day
200.0g USD 5650.0 2 Weeks
500.0g USD 8650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: AZD-6140; AZD6140; AZD 6140; AR-C 126532XX; AR-C-126532XX; AR-C126532XX; Ticagrelor; brand name: Brilinta; Brilique; Possia

IUPAC/Chemical Name: (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol


InChi Code: InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

SMILES Code: O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 522.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016 Apr;173(7):1163-78. doi: 10.1111/bph.13429. Epub 2016 Feb 24. Review. PubMed PMID: 26758983.

2: Guimarães PO, Tricoci P. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Expert Opin Pharmacother. 2015;16(13):1983-95. doi: 10.1517/14656566.2015.1074180. Epub 2015 Jul 29. Review. PubMed PMID: 26224244.

3: Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Am J Cardiol. 2015 Sep 1;116(5):809-17. doi: 10.1016/j.amjcard.2015.05.058. Epub 2015 Jun 4. Review. PubMed PMID: 26119655.

4: Harding SA, Van Gaal WJ, Schrale R, Gunasekara A, Amerena J, Mussap CJ, Aylward PE. Practical experience with ticagrelor: an Australian and New Zealand perspective. Curr Med Res Opin. 2015 Aug;31(8):1469-77. doi: 10.1185/03007995.2015.1058247. Epub 2015 Jun 30. Review. PubMed PMID: 26086451.

5: Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet. 2015 Nov;54(11):1125-38. doi: 10.1007/s40262-015-0290-2. Review. PubMed PMID: 26063049; PubMed Central PMCID: PMC4621714.

6: Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015 Jun;13(6):931-42. doi: 10.1111/jth.12907. Epub 2015 Apr 21. Review. PubMed PMID: 25809392.

7: Dhillon S. Ticagrelor: a review of its use in adults with acute coronary syndromes. Am J Cardiovasc Drugs. 2015 Feb;15(1):51-68. doi: 10.1007/s40256-015-0108-5. Review. PubMed PMID: 25672642.

8: Chong AY, So DY. Ticagrelor for the treatment of peripheral arterial disease. Expert Opin Investig Drugs. 2014 Dec;23(12):1737-43. doi: 10.1517/13543784.2014.974803. Epub 2014 Nov 6. Review. PubMed PMID: 25376000.

9: Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):555-60. doi: 10.1177/2048872614554108. Epub 2014 Sep 29. Review. PubMed PMID: 25267878; PubMed Central PMCID: PMC4657388.

10: Alexopoulos D, Xanthopoulou I, Storey RF, Bliden KP, Tantry US, Angiolillo DJ, Gurbel PA. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. Am Heart J. 2014 Oct;168(4):530-6. doi: 10.1016/j.ahj.2014.06.026. Epub 2014 Jul 11. Review. PubMed PMID: 25262263.

11: Rognoni A, Cavallino C, Lupi A, Secco GG, Veia A, Bacchini S, Rosso R, Brunelleschi S, Rametta F, Bongo AS. Ticagrelor: a novel drug for an old problem. Recent Pat Cardiovasc Drug Discov. 2014;9(1):51-7. Review. PubMed PMID: 25174338.

12: Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014 Oct;34(10):1077-90. doi: 10.1002/phar.1477. Epub 2014 Aug 28. Review. PubMed PMID: 25164528; PubMed Central PMCID: PMC4282310.

13: Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014 Jun 17;63(23):2503-9. doi: 10.1016/j.jacc.2014.03.031. Epub 2014 Apr 23. Review. PubMed PMID: 24768873.

14: Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014 Apr;167(4):437-444.e5. doi: 10.1016/j.ahj.2013.12.020. Epub 2014 Jan 6. Review. PubMed PMID: 24655690.

15: Bonhomme F, Fontana P, Reny JL. How to manage prasugrel and ticagrelor in daily practice. Eur J Intern Med. 2014 Mar;25(3):213-20. doi: 10.1016/j.ejim.2014.01.016. Epub 2014 Feb 12. Review. PubMed PMID: 24529662.

16: Morici N, Colombo P, Mafrici A, Oreglia JA, Klugmann S, Savonitto S. Prasugrel and ticagrelor: is there a winner? J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):8-18. doi: 10.2459/JCM.0b013e328364561b. Review. PubMed PMID: 24500235.

17: Tsang K, Hartmark-Hill JR. Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome. Am Fam Physician. 2013 Dec 15;88(12):821-2. Review. PubMed PMID: 24364545.

18: Serebruany VL, Sibbing D, DiNicolantonio JJ. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology. 2014;127(1):20-4. doi: 10.1159/000354876. Epub 2013 Oct 26. Review. PubMed PMID: 24192670.

19: Bansilal S, Bonaca MP, Sabatine MS. Ticagrelor for acute coronary syndromes. Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1473-84. doi: 10.1586/14779072.2013.839205. Epub 2013 Oct 23. Review. PubMed PMID: 24147518.

20: Norgard NB, Dinicolantonio JJ. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med. 2013 Jul;125(4):91-102. doi: 10.3810/pgm.2013.07.2682. Review. PubMed PMID: 23933898.